NextCure, Inc. (NXTC)

NextCure Statistics

Total Valuation

NextCure has a market cap or net worth of $26.28 million. The enterprise value is -$3.95 million.

Market Cap	26.28M
Enterprise Value	-3.95M

Important Dates

The last earnings date was Wednesday, November 5, 2025, after market close.

Earnings Date	Nov 5, 2025
Ex-Dividend Date	n/a

Share Statistics

NextCure has 2.68 million shares outstanding. The number of shares has increased by 0.78% in one year.

Current Share Class	2.68M
Shares Outstanding	2.68M
Shares Change (YoY)	+0.78%
Shares Change (QoQ)	+1.75%
Owned by Insiders (%)	1.65%
Owned by Institutions (%)	17.60%
Float	1.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.76
P/TBV Ratio	0.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.71, with a Debt / Equity ratio of 0.19.

Current Ratio	3.71
Quick Ratio	3.29
Debt / Equity	0.19
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -105.88% and return on invested capital (ROIC) is -62.88%.

Return on Equity (ROE)	-105.88%
Return on Assets (ROA)	-53.12%
Return on Invested Capital (ROIC)	-62.88%
Return on Capital Employed (ROCE)	-173.04%
Revenue Per Employee	n/a
Profits Per Employee	-$1.42M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.44% in the last 52 weeks. The beta is 1.56, so NextCure's price volatility has been higher than the market average.

Beta (5Y)	1.56
52-Week Price Change	-39.44%
50-Day Moving Average	7.22
200-Day Moving Average	6.53
Relative Strength Index (RSI)	52.22
Average Volume (20 Days)	85,932

Short Selling Information

The latest short interest is 10,909, so 0.41% of the outstanding shares have been sold short.

Short Interest	10,909
Short Previous Month	14,748
Short % of Shares Out	0.41%
Short % of Float	0.64%
Short Ratio (days to cover)	0.88

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-63.86M
Pretax Income	-60.93M
Net Income	-60.93M
EBITDA	-61.20M
EBIT	-63.86M
Earnings Per Share (EPS)	-$26.00

Balance Sheet

The company has $35.31 million in cash and $5.59 million in debt, giving a net cash position of $29.72 million or $11.10 per share.

Cash & Cash Equivalents	35.31M
Total Debt	5.59M
Net Cash	29.72M
Net Cash Per Share	$11.10
Equity (Book Value)	29.65M
Book Value Per Share	12.68
Working Capital	29.23M

Cash Flow

In the last 12 months, operating cash flow was -$54.13 million and capital expenditures -$136,000, giving a free cash flow of -$54.27 million.

Operating Cash Flow	-54.13M
Capital Expenditures	-136,000
Free Cash Flow	-54.27M
FCF Per Share	-$20.28

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NextCure does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.78%
Shareholder Yield	-0.78%
Earnings Yield	-236.42%
FCF Yield	-210.57%

Analyst Forecast

The average price target for NextCure is $25.50, which is 159.67% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$25.50
Price Target Difference	159.67%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-50.73%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:12.

Last Split Date	Jul 14, 2025
Split Type	Reverse
Split Ratio	1:12

Scores

Altman Z-Score	n/a
Piotroski F-Score	1